These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 29254892)
1. Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy. Wang ZH; Li DD; Chen WL; You QD; Guo XK Bioorg Med Chem; 2018 Jan; 26(2):356-365. PubMed ID: 29254892 [TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction. Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859 [TBL] [Abstract][Full Text] [Related]
3. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236 [TBL] [Abstract][Full Text] [Related]
4. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface. Ren J; Xu W; Tang L; Su M; Chen D; Chen YL; Zang Y; Li J; Shen J; Zhou Y; Xiong B Bioorg Med Chem Lett; 2016 Sep; 26(18):4472-4476. PubMed ID: 27528435 [TBL] [Abstract][Full Text] [Related]
6. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. Patel A; Dharmarajan V; Vought VE; Cosgrove MS J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245 [TBL] [Abstract][Full Text] [Related]
7. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. Karatas H; Townsend EC; Bernard D; Dou Y; Wang S J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550 [TBL] [Abstract][Full Text] [Related]
9. Human CpG binding protein interacts with MLL1, MLL2 and hSet1 and regulates Hox gene expression. Ansari KI; Mishra BP; Mandal SS Biochim Biophys Acta; 2008 Jan; 1779(1):66-73. PubMed ID: 18082152 [TBL] [Abstract][Full Text] [Related]
10. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation. Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145 [TBL] [Abstract][Full Text] [Related]
11. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966 [TBL] [Abstract][Full Text] [Related]
13. Targeting human SET1/MLL family of proteins. Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335 [TBL] [Abstract][Full Text] [Related]
14. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. Cosgrove MS; Patel A FEBS J; 2010 Apr; 277(8):1832-42. PubMed ID: 20236310 [TBL] [Abstract][Full Text] [Related]
15. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Chen CW; Armstrong SA Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503 [TBL] [Abstract][Full Text] [Related]
16. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Li BE; Ernst P Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566 [TBL] [Abstract][Full Text] [Related]
17. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. Li X; Song Y J Hematol Oncol; 2021 Apr; 14(1):56. PubMed ID: 33823889 [TBL] [Abstract][Full Text] [Related]
18. The internal interaction in RBBP5 regulates assembly and activity of MLL1 methyltransferase complex. Han J; Li T; Li Y; Li M; Wang X; Peng C; Su C; Li N; Li Y; Xu Y; Chen Y Nucleic Acids Res; 2019 Nov; 47(19):10426-10438. PubMed ID: 31544921 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709 [TBL] [Abstract][Full Text] [Related]
20. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]